Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

TARGET
January 09, 2018
Nature Medicine

TARGET investigator’s study of nearly 1,000 pediatric acute myeloid leukemia (AML) cases reveals marked differences between the genomic landscapes of pediatric and adult AML and offers directions for future work.

TARGET
December 12, 2017
Nature Medicine

TARGET’s AML researchers demonstrate that recurrent structural alterations and age-specific mutational profiles can be used stratify pediatric subjects in terms of both overall and progression-free survival, and highlight the need for age-tailored targeted therapies for pediatric AML.

CTD²
December 01, 2017
Nature Genetics

CTD2 researchers at DFCI developed CERES, a computational approach to improve the specificity of genome-wide loss-of-function CRISPR-Cas9 screens by decreasing the discovery of false-positives.

CTD²
November 24, 2017
Bioinformatics

CTD2 scientists at Emory University developed the OncoPPi Portal, an interactive web resource to explore cancer-relevant protein-protein interactions that were experimentally identified in cancer cell lines.

CTD²
November 22, 2017
Cell Systems

CTD2 scientists used Project Achilles (RNAi screening) data in a community DREAM challenge (that assessed computational models focused on biomedical research problems) to predict the gene essentiality. This study provides insights into factors influencing the ability to predict gene essentiality.

TARGET
November 14, 2017
Oncotarget

TARGET investigators examined whether circulating miRNAs can be used as prognostic biomarkers in osteosarcoma patients. miR-21, miR-221, and miR-106a were found to be expressed significantly higher in cancer samples and were correlated with outcome.  

CTD²
November 09, 2017
Nature

CTD2 scientists at UCSF (1), Broad Institute, and TGen have identified that drug-tolerant persister cancer cells from multiple tumor types that survive chemotherapy were found to be vulnerable to chemical inhibition or genetic loss of function of GPX4.

CTD²
November 06, 2017
Nature Genetics

UCSF (1) researchers identified genetic alterations that assist primary drivers, as co-drivers, that promote tumor growth and drug resistance in advanced-stage EGFR-mutant lung cancers.

CTD²
November 01, 2017
Cancer Research

CTD2 scientists at UT MD Anderson Cancer Center developed a user-friendly bioinformatic resource, The Cancer Proteome Atlas (TCPA). This resource contains the expression levels of key cancer proteins (characterized by reverse-phase protein arrays) from patient tumors and cancer cell lines.

TARGET
October 25, 2017
Journal of Clinical Oncology

TARGET’s AML researchers identified abundant expression of miR-106a, a marker for treatment resistance, in relapsed and refractory pediatric AML through a comprehensive miRNA profile to identify potential biomarkers as predictors for improved outcomes.

Pages